TEAM FRESH WIND recent publication on TIL therapy clinical application
“TEAM FRESH WIND” led by Dr. Satoko Matsueda has recently published a paper tittle as. “Successful ex vivo expansion of tumor...
“TEAM FRESH WIND” led by Dr. Satoko Matsueda has recently published a paper tittle as. “Successful ex vivo expansion of tumor...
"Bold Goals for U.S. Biotechnology and Biomanufacturing" The White House has announced new goals and priorities to promote biotechnology...
Immune Monitoring and Breakthrough Immunotherapies More immunotherapies In Feb 2023, FDA granted the “breakthrough therapy designation”...
A cell therapy that may cure cancers The human immune system is extremely complex. When most people think of the immune system, we think...
NEJM Paper (a Randomized Open-Label Trial) Walkthrough Treating advanced melanoma, a dangerous form of skin cancer, has become a...
Neoantigens, tumor specific antigens (TSAs), and tumor associated antigens (TAAs) are ultimate targets for cancer immunotherapies....
Late last year FDA removed the requirements for animal testing before moving into clinical testing. This is a timely move in the right...
Tumor infiltrating lymphocytes (TILs) are a type of immune cell that is found within a tumor. Neoantigens are a type of antigen that is...